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Background: The role of postoperative radiotherapy (PORT) after 
surgical resection of non–small-cell lung cancer (NSCLC) remains 
controversial. Although pertinent randomized evidence is lacking, 
historical studies have shown a survival detriment, partially attrib-
uted to antiquated radiotherapy techniques and supratherapeutic 
doses, whereas more recent nonrandomized data have suggested a 
survival benefit for PORT in appropriate patients. This analysis reas-
sesses the impact of PORT in a modern cohort of patients with par-
ticular attention to radiotherapy details.
Methods: Patients treated with margin-negative (R0) surgical resec-
tion of NSCLC with complete adjuvant treatment information were 
identified within the National Cancer Database. Overall survival 
(OS) was compared between patients based upon pathologic stage of 
disease, histologic subtype, and details of adjuvant therapy delivered.
Results: We identified 30,552 patients treated for stages II–IIIA 
NSCLC in National Cancer Database between 1998 and 2006. 
Histology was adenocarcinoma in 16,482, squamous cell in 9847, 
large cell in 1715 and other in 2562. Overall, 3430 patients (11.2%) 
received PORT, and 23.8% of N2 patients received PORT. There was 
a detriment in 5-year OS with PORT for pathologically N0 (48 versus 
37.7%, p < 0.001) and N1 patients (39.4 versus 34.8%, p < 0.001), 
although 5-year OS was improved with PORT in N2 patients (27.8 
versus 34.1%, p < 0.001). Importantly, PORT dose was found to have 
a significant impact on OS. Patients who received 45 to 54 Gy dem-
onstrated superior survival relative to patients without PORT (5-year 
OS 38 versus 27.8%, p < 0.001), although patients who received 
greater than 54 Gy had equivalent survival to patients treated without 
PORT (5-year OS 27.6 versus 27.8%, p = 0.784). PORT with doses 
of 45 to 54 Gy remained significantly associated with improved OS 
on multivariate analysis (hazard ratio for death 0.85, 95% confidence 
interval 0.76–0.94, p < 0.001).
Conclusions: PORT delivered with modern techniques with appro-
priate doses continues to demonstrate a survival benefit in patients 
with positive mediastinal nodal metastases, and therefore should 
remain a standard of care for this population.
Key Words: Postoperative radiotherapy, Non–small-cell lung cancer, 
Postoperative radiotherapy, National Cancer Database.
(J Thorac Oncol. 2015;10: 148–155)
The management of non–small-cell lung cancer (NSCLC) continues to evolve with improvements in diagnostic imag-
ing, surgical techniques, and adjuvant therapies. The mainstay 
of treatment remains surgical resection, with an overall sur-
vival (OS) benefit from the addition of adjuvant chemother-
apy in appropriate patients.1 What remains controversial is the 
appropriate use of postoperative radiotherapy (PORT). Early 
data regarding PORT from a foregone era of radiotherapy 
(RT) for NSCLC failed to show a benefit of such treatment in 
all patients, and actually demonstrated a survival decrement 
for patients with N0 or N1 nodal status.2 However, the PORT 
meta-analysis is beset by numerous limitations that render it 
nearly irrelevant to current clinical practice.3 Treatment tech-
niques in the included trials employed unacceptably large 
doses per fraction, two-dimensional RT, cobalt-based RT, and 
imprecise dosimetry which led to increased treatment mor-
bidity and mortality, perhaps negating any potential disease 
control benefit.
An OS benefit from PORT in patients with N2 nodal 
disease has subsequently been demonstrated both by a popula-
tion-based retrospective report by Lally et al. and a subgroup 
analysis from the Adjuvant Navelbine International Trialist 
Association (ANITA) trial wherein patients were treated with 
PORT in a nonrandomized fashion.4,5 The PORT meta-analy-
sis failed to show this result, due to an increase in intercurrent 
deaths among PORT patients and a failure to adequately treat 
the areas most at-risk for local recurrence.6,7 These discordant 
results have resulted in significant controversy in the lung can-
cer community, and have thereby limited the application of 
PORT in seemingly appropriate patients.
Given the stepwise advances in the treatment of 
NSCLC patients, as well as the technological improvements 
in RT planning and delivery, we sought to re-evaluate the out-
comes of patients treated in the modern era with PORT in a 
large population-based analysis using the National Cancer 
Database (NCDB). A significant advantage of this approach 
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over previously published retrospective analyses is that radia-
tion dose and treatment modality can be incorporated into the 
analysis. In addition, NCDB data allows us to control for mar-
gin status, chemotherapy use, and Charlson/Deyo comorbidity 
score, leading to a more precise analysis of the true benefit of 
RT. We hypothesized that PORT delivered with modern RT 
techniques and standard radiation doses would be associated 
with an OS benefit in patients with mediastinal nodal (N2) 
involvement after margin negative resection.
MATERIALS AND METHODS
National Cancer Database
The NCDB is a joint project of the Commission on 
Cancer of the American College of Surgeons and the American 
Cancer Society. The NCDB records information regarding 
approximately 70% of newly diagnosed cancers in the United 
States, including treatment details such as sequencing of ther-
apies, dose, technique, and target.8 The data used in this study 
are derived from a de-identified NCDB file, The American 
College of Surgeons and the Commission on Cancer have not 
verified and are neither responsible for the analytic or statisti-
cal methodology employed nor the conclusions drawn from 
these data by the investigator. This study was approved by the 
Yale Human Investigation Committee.
Patient Identification
Patients 21 years or older with American Joint 
Commission on Cancer stage II–IIIA NSCLC treated with 
either lobectomy or pneumonectomy and for whom pathology, 
chemotherapy, and RT details were recorded were included. 
Information regarding tumor size, laterality, and number of 
involved lymph nodes was required. Patients were classified 
as having received chemotherapy alone, chemotherapy and 
RT, RT alone, or neither. Patients with pathologic nodal stage 
N3 and/or positive surgical margins were excluded. Patients 
surviving less than 4 months from surgery were excluded to 
avoid influence of late surgical morbidity on study outcomes. 
Finally, patients treated with radiation doses less than 45Gy or 
RT to targets other than the lung were excluded.
Statistical Analyses
Demographic, histopathologic, and treatment details 
were compared between patients who did and did not receive 
PORT using independent samples t tests and χ2 analyses as 
appropriate. The primary objective of this study was to evalu-
ate the impact of PORT on OS among patients based on 
pathologic nodal stage. Thus, Kaplan–Meier analyses of OS 
were performed comparing patients within each N-stage sub-
group based on receipt of PORT. Information pertaining to 
local-regional recurrence is not recorded in NCDB, and thus 
is not reported herein. Patients grouped by N stage (rather 
than primary tumor size) were given similar grouping in prior 
publications, to facilitate comparison of our findings with the 
literature. However, tumor size was considered in multivariate 
analyses. Several markers of nodal disease burden and extent 
of surgical assessment, including the number of nodes excised, 
number of nodes positive, and the nodal ratio (number positive 
divided by number excised) were used to compare OS out-
comes among patients. For comparisons of number of nodes 
excised, a cutoff of ten (≤9 versus ≥10 nodes) was used.9 
A cut-point of 50% was used for nodal ratio (≤50% versus 
>50%). Univariate Kaplan–Meier and Cox regression analy-
ses were performed based on applicable covariates including 
age (<60 versus ≥60 years), gender, surgery type, tumor size, 
nodal stage, histologic subtype, comorbid illness, and receipt 
of chemotherapy. Multivariate Cox regression analyses of OS 
were performed with receipt of PORT and factors significant 
on univariate tests as covariates, of which all were included.
Next, we sought to determine if outcomes after PORT 
differed based on details of RT. Within each N-stage strata, 
patients were compared by dose (45–54 Gy versus >54–60 Gy 
versus >60 Gy) and RT technique (if recorded, 3D-conformal 
RT versus intensity-modulated radiation therapy). Kaplan–
Meier analyses were used for each comparison separately, 
and significant factors were integrated into multivariate Cox 
regression analyses as described above.
RESULTS
We identified 30,552 patients treated between 1998 and 
2006 matching the criteria outlined above. Median follow-
up was 7.5 years. Overall, 3340 (11.2%) of patients met our 
inclusion criteria as having received PORT. The median dose 
among these patients was 54.0 Gy. Demographics, patho-
logic findings, and treatment details are shown in Table 1. In 
univariate analyses of OS, patients with adenocarcinoma or 
squamous cell carcinoma appeared to have superior outcomes 
relative to patients with large cell carcinoma (p < 0.001). Age 
less than 60, women sex, Charlson/Deyo score of 0, lobec-
tomy (versus pneumonectomy), receipt of chemotherapy, 
right-sided primary tumor site, smaller tumor size and less 
advanced nodal stage were also associated with better OS in 
univariate analyses (all p < 0.001; Table 2).
Among patients with pathologically negative nodes, 
PORT resulted in a statistically significant reduction in 5-year 
OS relative to surgery alone (37.7 versus 48%, p = 0.009, 
respectively; Fig. 1). Similar findings were demonstrated 
among patients with N1 nodal disease (34.8 versus 39.4%, 
respectively; p < 0.001; Fig. 2). In both N-stage strata, surgery 
plus RT alone resulted in inferior survival relative to surgery 
alone, surgery plus chemotherapy, and surgery plus chemo-
therapy and RT (data not shown, p < 0.001). In N1 patients, 
the number of nodes positive and nodal ratio independently 
influenced OS on multivariate analysis (Table 3). However, 
these factors did not influence the relationship between receipt 
of PORT and OS, confirming that we were unable to identify a 
subset of N1 patients that would benefit from PORT (Table 3).
Among patients with N2 disease, however, the addition 
of PORT resulted in an absolute 5-year OS benefit of 6.3% 
(34.1 versus 27.8%, p < 0.001; Fig. 3A). In this group of 
patients, 5-year OS was best among patients who received sur-
gery, chemotherapy, and PORT, followed by surgery plus che-
motherapy, surgery plus PORT, and surgery alone (36.7 versus 
33.6 versus 23.84 versus 23.4%, respectively, p < 0.001; Fig. 
3B). The survival benefit with PORT persisted in the N2 sub-
group despite adjusting for indicators of nodal disease burden 
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TABLE 1.  Patient and Treatment Characteristics
Overall  
Sample (30,552)
Radiation
No-RT (27,122) Postop RT (3430) p Value
Age (mean) 66.3 66.6 63.9 <0.0001
Sex
  Male 16,489 (54.0%) 14,653 (54.0%) 1836 (53.5%) 0.59
  Female 14,063 (46.0%) 12,469 (46.0%) 1594 (46.5%)
Race
  White 27,303 (89.4%) 24,244 (89.4%) 3059 (89.2%) 0.869
  Black 2313 (7.6%) 2052 (7.6%) 261 (7.6%)
  Other 936 (3.1%) 826 (3.0%) 110 (3.2%)
Charleson–Deyo Score
  0 9608 (31.4%) 8002 (29.5%) 1606 (46.8%) <0.0001
  1–2 6990 (22.9%) 6081 (22.4%) 909 (26.5%)
  Unknown 13,954 (45.7%) 13,039 (48.1%) 915 (26.7%)
Type of surgery
  Pneumonectomy 4884 (16.0%) 4427 (16.3%) 457 (13.3%) <0.0001
  Lobectomy 25,668 (84.0%) 22,695 (83.7%) 2973 (86.7%)
Histology
  Adenocarcinoma 16,428 (53.8%) 14,586 (53.8%) 1842 (53.7%) 0.008
  Squamous cell carcinoma 9847 (32.2%) 8794 (32.4%) 1053 (30.7%)
  Large cell carcinoma 1715 (5.6%) 1515 (5.6%) 200 (5.8%)
  Other/unknown 2562 (8.4%) 2227 (8.2%) 335 (9.8%)
Tumor size (cm)
  ≤3.0 13,102 (42.9%) 11,710 (43.2%) 1392 (40.6%) 0.002
  3.1–5.0 10,288 (33.7%) 9128 (33.7%) 1160 (33.8%)
  >5.0 7162 (23.4%) 6284 (23.2%) 878 (25.6%)
Nodal status
  N0 5836 (19.1%) 5387 (19.9%) 449 (13.1%) <0.0001
  N1 17,737 (58.1%) 16,416 (60.5%) 1321 (38.5%)
  N2 6979 (22.8%) 5319 (19.6%) 1660 (48.4%)
Pathologic stage group
  II 385 (1.3%) 364 (1.3%) 21 (0.6%) <0.0001
  IIA 5699 (18.7%) 5346 (19.7%) 353 (10.3%)
  IIB 13,014 (42.6%) 11,955 (44.1%) 1059 (30.9%)
  III 81 (0.3%) 71 (0.3%) 10 (0.3%)
  IIIA 7618 (24.9%) 5917 (21.8%) 1701 (49.6%)
  IIIB 3755 (12.3) 3469 (12.8%) 286 (8.3%)
Laterality
  Right 16,238 (53.1%) 14,402 (53.1%) 1836 (53.5%) 0.65
  Left 14,314 (46.9%) 12,720 (46.9%) 1594 (46.5%)
Chemotherapy receipt
  Yes 10,494 (34.3%) 8188 (30.2%) 2306 (67.2%) <0.0001
  No 20,058 (65.7%) 18,934 (69.8%) 1124 (32.8%)
Radiation dose
  45–54 Gy - 1985 (57.9%)
  55–60 Gy - 811 (23.6%)
  >60 Gy - 633 (18.5%)
Treatment modality
  3D conformal RT - 288 (83.2%)
  IMRT - 58 (16.8%)
RT, radiotherapy; IMRT, intensity-modulated radiation therapy.
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(Table 3), demonstrating that N2 patients benefit from PORT 
regardless of the percentage of positive lymph nodes examined.
Radiation dose appeared to have a significant effect on 
OS. Among N2 patients who received surgery, chemother-
apy, and PORT, patients receiving 45 to 54Gy had superior 
outcomes relative to patients treated to higher doses (5-year 
OS 41% for 45–54 Gy versus 32.7% for >54–≤60Gy versus. 
26.6% for >60 Gy, p < 0.001; Fig. 4A). Among all N2 patients 
(i.e., not restricted to just patients receiving surgery, chemo-
therapy, and PORT), as shown in Figure 4B, OS was similar 
between patients who were treated with greater than 54 Gy 
and those who did not receive PORT (5-year OS 27.6 versus 
27.8%, respectively, p = 0.784), whereas OS with PORT to 
45–54 Gy was superior (5-year OS 38 versus 27.8% without 
RT, p < 0.001). There was no effect of RT modality on median 
OS in univariate analyses (5-year OS 37.7% for 3DCRT ver-
sus 33% for intensity-modulated radiation therapy, p = 0.829) 
although only 11.3% of irradiated patients in the sample had 
usable data for this analysis (176 of 1560). The remainder had 
nonspecific descriptors of RT beam energy (i.e., 6–10 mega-
voltage photons) without indication of RT modality.
TABLE 2.  Results of Kaplan–Meier Analyses of Effects of 
Covariates on OS
5-Year OS HR (95% CI) p Value
Age
  <60 47.7% - <0.001
  ≥60 35.4% 1.40 (1.35–1.45)
Sex
  Male 35% - <0.001
  Female 42.4% 0.79 (0.77–0.82)
Charlson/Deyo score
  0 43% - <0.001
  1–2 37.2% 1.18 (1.13–1.23)
Surgery type
  Lobectomy 38.9% - <0.001
  Pnuemonectomy 35.7% 1.15 (1.1–1.2)
Histology
  Large cell carcinoma 36.8% - <0.001
  Adenocarcinoma 39% 0.85 (0.79–0.90)
  Squamous cell carcinoma 38.6% 0.89 (0.84–0.95)
  Other 34.9% 0.99 (0.91–1.07)
Tumor size
  ≤3 cm 43% - <0.001
  >3–≤5 cm 36.7% 1.23 (1.19–1.27)
  > 5 cm 32.4% 1.45 (1.42–1.53)
N-Stage
  N0 47.2% - <0.001
  N1 39.1% 1.23 (1.18–1.28)
  N2 29.3% 1.63 (1.55–1.70)
Chemotherapy
  No 35.7% - <0.001
  Yes 43.5% 0.79 (0.77–0.82)
Laterality
  Right 39.1% - 0.006
  Left 37.6% 1.04 (1.01–1.07)
OS, overall survival; HR, hazard ratio; CI, confidence interval.
FIGURE 1.  Comparison of OS among node-negative 
patients based on receipt of PORT. OS, overall survival; PORT, 
postoperative radiotherapy.
FIGURE 2.  Comparison of OS in patients with N1 nodal dis-
ease based upon receipt of PORT. OS, overall survival; PORT, 
postoperative radiotherapy.
152 Copyright © 2014 by the International Association for the Study of Lung Cancer
Corso et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 1, January 2015
Multivariate analyses were constructed for patients with 
N2 nodal disease with age, sex, Charlson/Deyo score, type of 
surgery, tumor size, histology, receipt of chemotherapy, and 
receipt of PORT as covariates. Results of multivariate analyses 
are shown in Table 4. This analysis demonstrated that receipt of 
PORT was no longer associated with improved OS among all 
N2 patients (hazard death [HR], 0.96; 95% confidence interval 
[CI], 0.88–1.05; p = 0.337). Given the observed effect of PORT 
dose on outcomes, a separate variable regarding RT was formed, 
with patients classified as having not received PORT, having 
received PORT to 45 to 54Gy, or PORT to greater than 54 Gy. 
The multivariate analysis of outcomes among N2 patients was 
repeated with this variable in place of receipt of PORT in a sec-
ond model (designated as “PORT Dose Model” in Table 4). This 
analysis demonstrated that receipt of PORT to 45 to 54 Gy was 
independently associated with improved OS relative to no PORT 
(HR, 0.85; 95% CI, 0.76–0.94; p = 0.002), whereas PORT to 
greater than 54 Gy was associated with a diminution in OS rela-
tive to no PORT (HR, 1.16; 95% CI, 1.03–1.31; p = 0.013).
DISCUSSION
The treatment of patients with locally advanced NSCLC 
is complex and varied, mirroring the heterogeneity of patients 
in this group and their disease characteristics. In those patients 
undergoing margin-negative surgical resection, distant failure 
remains the likeliest site of relapse, calling into question the 
value of further locoregional therapy in the form of PORT.10 
However, the findings of several studies have suggested that 
in appropriately selected patients with mediastinal nodal 
(N2) metastases, PORT results in a significant OS benefit.4,5 
We observed a similar advantage to PORT among all N2 
patients (regardless of chemotherapy receipt), with an abso-
lute 5-year OS benefit of 6.1% when compared with patients 
not receiving PORT, which approximates the 7% 5-year OS 
benefit observed by Lally et al.5 This OS benefit persisted for 
patients treated with now-standard doses, even when adjusting 
for receipt of chemotherapy and comorbidity, which the Lally 
analysis was unable to assess.
Despite the positive findings of prior studies regard-
ing PORT, its use in NSCLC patients with N2 nodal disease 
is low and perhaps declining.11,12 This may be the lingering 
byproduct of the concerning findings from the PORT meta-
analysis, which showed no benefit, and even a detriment to 
some patients, with PORT.2 However, the outdated nature of 
RT techniques, including supratherapeutic doses and anti-
quated field arrangements, in the amassed trials renders the 
findings of the PORT meta-analysis nonapplicable to current 
practice. That is because methodological advancements in 
conformal dose delivery have eliminated the excess of deaths 
from intercurrent disease (including cardiac and lung disease) 
that had previously obscured the survival benefit of PORT 
in N2 patients.6,13–16 In addition, many patients in the PORT 
meta-analysis received 60 Gy, which in our study produced 
statistically similar OS outcomes relative to patients who did 
not receive PORT.
In our multivariate analysis of OS for patients with 
N2 nodal disease, we observed that the effect of PORT on 
OS was no longer significant, although this was comparing 
patients based on the receipt of any dose of PORT versus 
no PORT. When the multivariate analysis was repeated with 
PORT delivery stratified by dose, those patients receiving cur-
rent standard doses of PORT after margin-negative resection 
(i.e., 45–54 Gy) demonstrated superior 5-year OS outcomes 
whereas those receiving an excessive dose of RT had inferior 
outcomes. This underscores the importance of the therapeutic 
window in delivering PORT. Given that NCDB does not con-
tain attributions of cause of death (i.e., cancer-specific sur-
vival, death due to pneumonitis, etc.), we cannot prove that 
the decrement in OS observed in patients treated with over 54 
Gy was due to treatment-related mortality. However, Machtay 
et al.13 demonstrated this association, with death from inter-
current disease in 2% of patients receiving less than 54 Gy 
versus 17% for patients treated with 54 Gy or higher.
Improvements unrelated to RT because the PORT meta-
analysis has also increased the potential benefit of adjuvant RT 
in appropriate patients. Patients in the modern era are staged 
with brain magnetic resonance imaging and positron emis-
sion tomography/computed tomography scans before surgery, 
which were unavailable to clinicians in the past decades, less-
ening the possibility that patients are offered aggressive local 
therapy while simultaneously harboring metastatic disease.11,17 
TABLE 3.  Unadjusted and Adjusted RRs for Effects of Nodal 
Parameters and Receipt of PORT on OS
Variable
Unadjusted Adjusted
RR 95% CI RR 95% CI
N1
  Receipt of PORT
   No 1.0 - 1.0 ─
   Yes 1.14 1.07–1.23 1.13 1.05–1.21
  Number nodes examined
   ≤9 1.0 - 1.0 -
   ≥10 0.96 0.90–1.01 0.89 0.86–0.93
  Number nodes positive
   1–3 1.0 - 1.0 -
   ≥4 1.35 1.28–1.44 1.39 1.32–1.47
  Ratio of nodes positive
   ≤0.5 1.0 - 1.0 -
   >0.5 1.50 1.41–1.60 1.56 1.47–1.66
N2
  Receipt of PORT
   No 1.0 - 1.0 -
   Yes 0.82 0.77–0.88 0.80 0.74–0.85
  Number nodes examined
   ≤9 1.0 - 1.0 -
   ≥10 0.89 0.85–0.92 0.95 0.90–1.01
  Number nodes positive
   1–3 1.0 - 1.0 -
   ≥4 1.40 1.32–1.47 1.38 1.30–1.46
  Ratio of nodes positive
   ≤0.5 1.0 - 1.0 -
   >0.5 1.57 1.49–1.67 1.53 1.44–1.64
PORT, postoperative radiotherapy; CI, confidence interval.
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Moreover, distant micrometastases are more effectively treated 
with current systemic therapies, rendering local failure a more 
important issue, further explaining the consistent OS benefit 
observed in this and many other modern studies of PORT.4,5,7 
Indeed, recent data support the assertion that PORT results in 
a substantial reduction in local recurrence, and that in turn this 
leads to an improvement in OS.18–21 The unavailability of local 
control information in the NCDB prohibited an assessment of 
the relationship between PORT and local control in this study.
The strengths of this study lie in the fact that it is the 
largest postoperative analysis of its kind and incorporates 
modern radiation dose information. Although its retrospec-
tive nature is a limitation, the large sample size reduces 
the potential for bias as a sole explanation of our findings. 
Nonetheless, patients may have been offered PORT because 
of a heightened sense of recurrence risk on the part of their 
physicians despite their margin-negative status. This may 
have influenced delivered doses as well. For example, we 
FIGURE 3.  Comparison of OS in patients with N2 nodal disease based upon receipt of PORT (A) and by adjuvant treatment (B). OS, 
overall survival.
FIGURE 4.  Overall survival comparisons based upon PORT dose delivered among patients receiving surgery, chemotherapy, 
and PORT (A) and among all N2 patients (B). PORT, postoperative radiotherapy.
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observed reduced OS among N2 patients treated with over 54 
Gy relative to 45–54 Gy. The former group of patients may 
have been perceived to be at a higher risk of local recurrence 
because of extranodal extension (which is not captured in 
NCDB) or another unmeasured factor. Hence, lower survival 
in the high dose group may have been due to factors associ-
ated with delivery of a high dose of RT, rather than the dose 
itself. This is unlikely, though, as the relationship between 
PORT doses over 54 Gy and heightened risk of death from 
intercurrent disease is well documented in the published lit-
erature and supportive of our findings.13
As is the case with other large national database studies, 
our analysis is limited by the absence of granular, patient-level 
information that informs everyday clinical decision making. 
Such details are often outside of the scope of cancer registries, 
or are undefined at the inception of a large cancer database 
such as the NCDB. Nonetheless, information pertaining to 
the preoperative assessment of patients (including magnetic 
resonance imaging brain, positron emission tomography/com-
puted tomography, and invasive mediastinal staging) or crite-
ria used to select patients for delivery of PORT would aid in 
the interpretation of our findings.
CONCLUSIONS
We observed that delivering PORT to patients with 
mediastinal nodal metastases after surgery and chemother-
apy results in a significant survival benefit, which is in part 
modified by delivered dose. PORT should remain a standard 
treatment option for such patients pending results of ongoing 
randomized trials.22
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